目的 觀察葛根素葡萄糖注射液聯(lián)合苯磺酸氨氯地平治療冠心病心絞痛的臨床療效。方法 選取鞍鋼集團(tuán)總醫(yī)院2014年5月-2016年5月收治的冠心病心絞痛患者80例，依據(jù)治療方法不同分為對(duì)照組和治療組，每組各40例。對(duì)照組患者口服苯磺酸氨氯地平片，5 mg/次，1次/d。治療組患者在對(duì)照組的基礎(chǔ)上靜脈滴注葛根素葡萄糖注射液，500 mg加入5%葡萄糖注射液250 mL，1次/d。兩組患者均連續(xù)治療1個(gè)月。觀察兩組的臨床療效，同時(shí)比較分析兩組患者心絞痛發(fā)作頻率、持續(xù)時(shí)間及硝酸甘油用量、左室收縮功能和不良反應(yīng)發(fā)生情況。結(jié)果 治療后，對(duì)照組和治療組總有效率分別為70.0%和92.5%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后兩組心絞痛發(fā)作次數(shù)、持續(xù)時(shí)間及硝酸甘油用量較同組治療前明顯降低，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療后，治療組心絞痛改善情況優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者每搏射血量（SV）、心臟指數(shù)（CI）和射血分?jǐn)?shù)（LVEF）變化比較差異均沒有統(tǒng)計(jì)學(xué)意義。治療后，兩組不良反應(yīng)發(fā)生率比較差異沒有統(tǒng)計(jì)學(xué)意義。結(jié)論 葛根素注射液聯(lián)合苯磺酸氨氯地平治療冠心病心絞痛具有顯著的療效，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the clinical efficacies of Puerarin and Glucose Injection combined with amlodipine besylate in treatment of coronary heart disease with angina pectoris. Methods Patients (80 cases) with coronary heart disease with angina pectoris from May 2014 to May 2016 in Ansteel Group Hospital were divided into control and treatment groups based on different treatments, and each group had 40 cases. Patients in the control group were po administered with Amlodipine Besylate Tablets, 5 mg/time, once daily. The patients in the treatment group were iv administered with Puerarin and Glucose Injection on the basis of the control group, 500 mg added into 5% glucose injection, once daily. The patients in two groups were treated for one month. After treatment, the clinical efficacy was evaluated, and the frequency and duration of angina pectoris, nitroglycerin dosage, left ventricular systolic function, and adverse reactions in two groups were compared. Results After treatment, the efficacies in the control and treatment groups were 70.0% and 92.5%, respectively, and there were differences between two groups (P<0.05). After treatment, frequency and duration of angina pectoris, and also nitroglycerin dosage of two groups were significantly decreased, and the differences were statistically significant in the same group (P<0.05). And after treatment, the improvement of symptoms in the treatment group was better than that in the control group, with significant differences between two groups (P<0.05). After treatment, there was no statistically significant difference in the changes of SV, CI, and LVEF between two groups. And after treatment, the differences were not statistically significant in the adverse reactions between two groups. Conclusion Puerarin and Glucose Injection combined with amlodipine besylate has a significant clinical efficacy in treatment of coronary heart disease with angina pectoris, which has a certain clinical application value.